ReviewInternational journal of hematology2024
The pathogenesis of cancer-associated thrombosis.
Review in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Efficacy and safety of low-dose versus standard-dose direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: a systematic review and meta-analysis.Proceedings (Baylor University. Medical Center) · 2026Pooled it
- Clot composition analysis in ischemic stroke of cancer patients: a systematic review.BMC neurology · 2026Pooled it
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- Article
- Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse Glioma.Journal of clinical medicine · 2026Article
- IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?Journal of thrombosis and thrombolysis · 2026Review
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients.Journal of surgical oncology · 2026Article
- Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts.Molecular biology reports · 2026Article
- Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.Cardio-oncology (London, England) · 2026Review
- The coagulation-inflammation axis in advanced cancer: associations with cardiovascular-thrombotic complications.Journal of thrombosis and thrombolysis · 2026Article
- Superficial Venous Thrombosis in Non-Varicose Veins: A Narrative Review.Journal of clinical medicine · 2026Review
- Anticoagulation Quality Improvement Project: Reducing Noncompliant Anticoagulation Administrations in Patients With Cancer and Thrombocytopenia.Clinical journal of oncology nursing · 2026Article
- Endothelial dysfunction markers in cervical cancer and their influence on patient outcome.Molecular biology reports · 2026Article
- Risk of Cancer After a Hospital Contact for Dyspnea: A Nationwide Danish Cohort Study.Clinical epidemiology · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors.Frontiers in immunology · 2026Review
- Characteristics of Cancer-Associated Thrombosis Based on Changes in Clinically Measurable Coagulation Factors and Coagulation/Fibrinolysis Markers in Patients with Cancer: A Multicenter Cross-Sectional Study.Annals of vascular diseases · 2026Article
- Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer have a higher risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), compared to the general population. Cancer-associated thrombosis (CAT) is a thrombotic event that occurs as a complication of cancer or cancer therapy. Major factors determining VTE risk in cancer patients include not only treatment history and patient characteristics, but also cancer type and site. Cancer types can be broadly divided into three groups based on VTE risk: high risk (pancreatic, ovarian, brain, stomach, gynecologic, and hematologic), intermediate risk (colon and lung), and low risk (breast and prostate). This implies that the mechanism of VTE differs between cancer types and that specific VTE pathways may exist for different cancer types. This review summarizes the specific pathways that contribute to VTE in cancer patients, with a particular focus on leukocytosis, neutrophil extracellular traps (NETs), tissue factor (TF), thrombocytosis, podoplanin (PDPN), plasminogen activator inhibitor-1 (PAI-1), the intrinsic coagulation pathway, and von Willebrand factor (VWF).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.